Investing in Cambridge: A Gateway to Breakthrough Life Sciences Innovations

Introduction

We are thrilled to invite you to our exclusive "Investing in Cambridge" reception, where we will present a select group of promising companies from the vibrant Cambridge Life Sciences ecosystem. This event will bring together cutting-edge innovators and leading investors to explore unique investment opportunities in some of the most exciting technologies and scientific research emerging today.

Why Cambridge? 

There can’t be many people on Earth untouched by a Cambridge idea. 

• A third of the world’s new drugs are made using Cambridge antibody technology. 
• Almost every global smart phone is powered with an Arm Holdings chip.
• Our understanding of DNA structure and the technology that allows us to read it all came from the city.
• Then there is in vitro fertilisation (IVF), Dolby sound, the two forefathers of computing, Charles Babbage and Alan Turing.
• It’s the city that discovered the Electron and the Neutron, built the jet engine and wrote down some of the first rules for Association Football.
   

With 124 Nobel Prizes and 23 billion-dollar businesses, Cambridge continues to lead in life sciences, fostering advancements in diagnostics, therapeutics, and biotechnologies that are reshaping healthcare globally.

Exclusive Early-Stage Investment Opportunities
This reception offers an extraordinary chance to get an early look at high-potential companies from Cambridge’s life sciences ecosystem, some of which are just emerging from stealth mode. These companies represent breakthrough technologies that could define the future of healthcare and medical innovation, offering investors a unique first-mover advantage.

Featured Companies 
We are excited to feature 10-15 innovative companies (more to be revealed at the event), several in stealth or newly out of stealth mode, with their representatives presenting the cutting-edge technologies shaping their ventures including:

1. Artios Pharma – Series C
   Artios Pharma develops treatments that target DNA Damage Response (DDR) pathways to kill or weaken cancer cells.
   Speaker: Andrew Muncey, COO & Interim CFO
2. Immutrin – Seed Stage
   Immutrin Ltd is generating transformative antibody treatments for systemic and local amyloidosis, targeting rare diseases.
   Speaker: Dr. Mihriban Tuna, CEO
   
3. Monument Therapeutics – Seed Stage
   Monument Therapeutics is developing precision medicine designed to treat psychiatric and neurological conditions.
   Speaker: Jenny Barnett, Co-Founder & CEO
   
4. Momentous Therapeutics – Stealth Stage
   Momentous Therapeutics has discovered a biochemical mechanism controlling immune system activation, aiming to release the turbo-charge the immense potential of cancer immunotherapy.
   Speaker: Arthur Kaser, Founder & CEO
   
5. OtoImmune – Pre-Seed/Stealth
   OtoImmune is revolutionizing autoimmune and inflammatory disease management by leveraging multi-omicanalysis and electronic health records (RWE). 
   Speaker: Jason Mellad, Director
   
6. OvartiX – Semi-Stealth
   The women’s health drug discovery company, OvartiX, whose scientist co-founder, Stasa Stankovic, unlocked the genetic factors that control ovarian ageing and function, a key to a number of reproductive disorders, such as infertility, polycystic ovary syndrome and menopause. The team is now working to discover new therapeutics to improve and treat women’s reproductive health.
   Speaker: Stasa Stankovic, Co-founder
   
7. PharmEnable Therapeutics – Seed/Series A
   PharmEnable Therapeutics is reimagining small molecule therapeutics through AI. We access the inaccessible, developing innovative drugs against targets that require the specificity of biologics, but that cannot be addressed by them due to physical access barriers.
   Speaker: Dr Hannah Sore, Co-Founder & CEO
   
8. PhoreMost – Series B 
   PhoreMost is developing technology for discovering targetable sites on cells or microbes that are involved in diseases have proved difficult to treat. 
   Speaker: Neil Torbett, CEO
   
9. Shift Bioscience – Seed Stage
   Shift Bioscience develops pharmaceuticals using AI technology to identify cell therapies that safely reset cells and tissues to a youthful state, focusing on longevity and aging.
   Speaker: Daniel Ives, Co-Founder & CEO
   
10. Synteny – Seed/Series A
    Synteny combines high diversity synthetic TCR libraries with AI for rational molecule design 
    Speaker: Lilly Wollman, Co-Founder & CEO
    
11. Qureight– Series A
    Qureight has developed a cloud based platform which uses AI to speed up drug development in lung and heart diseases. 
    Speaker: Muhunthan Thillai, Co-Founder & CEO
    
    

Event Schedule

• Company Pitches (17:45 – 18:15): Presentations from featured companies unveiling their groundbreaking technologies.
• Networking Session: An opportunity to connect with company founders, researchers, and fellow investors, fostering relationships and exploring potential partnerships.
  
  

Contact Us
For more information, please contact: investor.engagement@cuhp.org.uk